Earnings summaries and quarterly performance for MARAVAI LIFESCIENCES HOLDINGS.
Executive leadership at MARAVAI LIFESCIENCES HOLDINGS.
Bernd Brust
Detailed
Chief Executive Officer
CEO
Christine Dolan
Detailed
Executive Vice President and General Manager, Cygnus Technologies
Kurt Oreshack
Detailed
Executive Vice President, General Counsel and Secretary
Peter Leddy
Detailed
Chief Administrative Officer
Rajesh Asarpota
Detailed
Chief Financial Officer
Rebecca Buzzeo
Detailed
Executive Vice President and Chief Commercial Officer
Board of directors at MARAVAI LIFESCIENCES HOLDINGS.
Research analysts who have asked questions during MARAVAI LIFESCIENCES HOLDINGS earnings calls.
Brandon Couillard
Wells Fargo & Company
3 questions for MRVI
Also covers: A, AVTR, BIO +10 more
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
3 questions for MRVI
Also covers: A, AVTR, CDXS +15 more
Matthew Hewitt
Craig-Hallum Capital Group LLC
3 questions for MRVI
Also covers: ACET, APYX, BHST +21 more
Matthew Stanton
Jefferies
3 questions for MRVI
Also covers: AZTA, BLFS, CDXS +5 more
Catherine Schulte
Baird
2 questions for MRVI
Also covers: A, CSTL, EXAS +7 more
Daniel Leonard
Stifel Financial Corp.
2 questions for MRVI
Also covers: A, AVTR, BIO +15 more
Justin Bowers
Deutsche Bank AG
2 questions for MRVI
Also covers: AMED, CON, CRL +9 more
Subbu Nambi
Guggenheim Securities
2 questions for MRVI
Also covers: BOLD, BRKR, CARS +16 more
Tejas Savant
Morgan Stanley
2 questions for MRVI
Also covers: ADPT, AKYA, AVTR +19 more
Anders Nowokowski
KeyBanc Capital Markets Inc.
1 question for MRVI
Conor Noel McNamara
RBC Capital Markets
1 question for MRVI
Also covers: AVTR, BIO, HOLX +6 more
Dan Arias
Stifel Financial Corp.
1 question for MRVI
Also covers: A, GH, ILMN +9 more
Douglas Schenkel
Wolfe Research, LLC
1 question for MRVI
Also covers: A, AVTR, BRKR +21 more
Kyle Crews
UBS
1 question for MRVI
Also covers: CERT, CYRX, MEDP
Madeline Mollman
Wolfe Research, LLC
1 question for MRVI
Also covers: PACB, TWST, TXG
Matthew Larew
William Blair & Company
1 question for MRVI
Also covers: AMED, ATR, DNA +10 more
Matthew Parisi
KeyBanc Capital Markets Inc.
1 question for MRVI
Also covers: AZTA, TKNO
Matt Larew
William Blair & Co.
1 question for MRVI
Also covers: AMED, MXCT, RGEN +5 more
Matt Sykes
Goldman Sachs Group, Inc.
1 question for MRVI
Also covers: CRL, CTKB, NTRA +4 more
Yuko Oku
Morgan Stanley
1 question for MRVI
Also covers: ADPT, GH, GRAL +7 more
Recent press releases and 8-K filings for MRVI.
Maravai Discusses Strategic Actions, Q4 Outlook, and 2026 Growth Drivers
MRVI
Management Change
Guidance Update
New Projects/Investments
- Maravai's new management team has implemented significant restructuring, removing over $50 million in annualized expenses through reduced headcount, facility rationalization, and CapEx reduction, aiming to return the business to revenue growth, positive EBITDA, and cash flow generation in 2026.
- The company reinstated guidance for the year, implying a $49 million Q4, a sequential step up driven by CDMO orders and GMP variability, and has improved visibility into its order book for the balance of the year and into 2026.
- Maravai introduced ModTail technology, which enhances mRNA protein expression durability and protection against degradation, opening new customer segments, and continues to refine IVT kits and leverage its mRNA builder e-commerce platform.
- The BST business grew 7% in Q3 and mid-single digits year-to-date, driven by MockViral kits and mass spec analytical services, with expectations for acceleration to high single-digit growth with further innovation.
- The company anticipates $10 million-$20 million per year in vaccine-related CleanCap revenue for 2026 and beyond, which will be integrated into the overall GMP business guidance.
Nov 19, 2025, 10:00 AM
Maravai Discusses Restructuring, 2026 Outlook, and Product Strategy at Jefferies Conference
MRVI
Management Change
Guidance Update
Revenue Acceleration/Inflection
- Maravai's new management team has implemented a restructuring plan, targeting over $50 million in annualized expense reductions through reduced headcount, facility rationalization, and CapEx cuts, aiming for a leaner organization and financial discipline.
- The company reinstated guidance, projecting a significant step up in Q4 due to CDMO orders and GMP variability, and is focused on returning to revenue growth and positive EBITDA and cash flow generation in 2026.
- Maravai anticipates $10 million-$20 million per year from vaccine-related CleanCap in 2026 and beyond, which will be integrated into the overall GMP business.
- Strategic product development emphasizes fewer, more impactful innovations like ModTail technology and IVT kits, while the commercial team focuses on larger orders (over $25,000) that represent 60% of revenue.
- The BST business grew 7% in Q3, driven by MockViral kits and analytical services, with MockViral having the potential to reach tens of millions of dollars.
Nov 19, 2025, 10:00 AM
Maravai CFO Discusses Restructuring, 2026 Outlook, and Q4 2025 Guidance
MRVI
Guidance Update
Layoffs
Revenue Acceleration/Inflection
- Maravai has undertaken significant restructuring efforts, resulting in over $50 million in annualized expense reductions through measures like a 25% headcount reduction, facility rationalization, and CapEx cuts.
- The company aims to return to revenue growth and positive EBITDA and cash flow generation in 2026, with a specific target of achieving adjusted EBITDA profitability in the back half of 2026.
- Guidance for Q4 2025 implies approximately $49 million in revenue, representing a sequential step-up driven by CDMO orders and GMP variability.
- Maravai anticipates $10 million-$20 million annually in vaccine-related CleanCap revenue for 2026 and beyond, which will be integrated into the overall GMP business.
- The company's commercial strategy includes focusing sales efforts on larger orders (over $25,000, representing 60% of revenue) and leveraging new products like ModTail technology to expand customer reach.
Nov 19, 2025, 10:00 AM
Maravai LifeSciences Details Strategic Review Progress and 2026 Outlook
MRVI
Guidance Update
Demand Weakening
New Projects/Investments
- Maravai LifeSciences Holdings Inc. (MRVI) has undergone a strategic review and restructuring, committing to over $50 million in annualized expense savings, with $3 million realized in Q3 2025 and an additional $7 million+ expected in Q4 2025.
- The company has improved its forecasting capabilities and reorganized sales teams to focus on higher-revenue orders, aiming to enhance revenue visibility and efficiency.
- Despite Nucleic Acid Purification (NAP) revenues being down 20% to $25 million in Q3 2025, Maravai anticipates a step back up with strong double-digit growth in Q4 2025 and expects growth in the NAP segment in 2026.
- Maravai projects $10 million to $20 million in COVID-related revenue for 2026, a significant increase from zero in 2025, following $66 million in 2024.
- The company expects to achieve positive EBITDA for the full year 2025, driven by cost benefits and expense reductions, which are anticipated to make the business profitable even at lower revenue levels.
Nov 12, 2025, 3:00 PM
Maravai LifeSciences Holdings Inc. Discusses Strategic Restructure, Cost Savings, and 2026 Outlook at Stifel Healthcare Conference
MRVI
Guidance Update
Revenue Acceleration/Inflection
Layoffs
- Maravai LifeSciences Holdings Inc. (MRVI) is undergoing a strategic restructure, committing to over $50 million in annualized expense savings, with $3 million realized in Q3 2025 and an additional $7 million+ expected in Q4 2025.
- The company expects to deliver positive EBITDA for the full year and has a full-year guide of $185 million.
- Nucleic Acid Production (NAP) revenues were $25 million in Q3 2025, down about 20% , but the company anticipates sequential growth in the segment and growth in 2026.
- After zero COVID revenue in 2025, Maravai expects $10-$20 million in COVID revenue for 2026.
- The Biosafety Testing (BST) segment saw 7% growth in the Americas and 17% growth in Europe in Q3 2025 and is projected to achieve mid to high single-digit growth going forward.
Nov 12, 2025, 3:00 PM
Maravai LifeSciences Reports Q3 2025 Results and Updates 2025 Guidance
MRVI
Earnings
Guidance Update
Demand Weakening
- Maravai LifeSciences reported Q3 2025 total revenue of $41.6 million, with Biologics Safety Testing (BST) revenue growing 7% to $16.3 million and Nucleic Acid Products (NAP) revenue declining 53% to $25.4 million year-over-year.
- The company recorded a GAAP net loss of $45.1 million and an adjusted EBITDA loss of $10.8 million in Q3 2025.
- For the full year 2025, Maravai projects revenue of approximately $185 million and an adjusted EBITDA loss of roughly $35 million, with an implied $3.5 million adjusted EBITDA loss for Q4.
- Management is on track to reduce annualized expenses by over $50 million and expects more than $7 million in sequential adjusted EBITDA improvements in Q4 2025, aiming for positive adjusted EBITDA and cash flow in 2026.
Nov 6, 2025, 10:00 PM
Maravai LifeSciences Announces Q3 2025 Results and 2025 Guidance
MRVI
Earnings
Guidance Update
Demand Weakening
- Maravai LifeSciences reported Q3 2025 revenue of $41.6 million, a GAAP net loss of $45.1 million, and an Adjusted EBITDA of ($10.8 million).
- The Nucleic Acid Products (NAP) segment's net sales were $25.4 million, down 53% year-over-year, primarily due to a non-recurring $18.2 million COVID GMP CleanCap® order in Q3 2024. In contrast, the Biologics Safety Testing (BST) segment grew 7% year-over-year to $16.3 million.
- For the full year 2025, Maravai LifeSciences anticipates revenue of approximately $185 million and Adjusted EBITDA of approximately ($35 million).
- The company is undergoing a restructuring to stabilize operations, reduce expenses, and strengthen its balance sheet, shifting its strategy towards sustainable, profitable growth.
Nov 6, 2025, 10:00 PM
Maravai LifeSciences Reports Q3 2025 Financial Results
MRVI
Earnings
Guidance Update
Demand Weakening
- Maravai LifeSciences reported Q3 2025 revenue of $41.6 million, a 39.7% decrease year-over-year, resulting in a net loss of $(45.1) million and Adjusted EBITDA of $(10.8) million.
- The revenue decline was largely due to a 52.9% decrease in Nucleic Acid Production revenue to $25.4 million, primarily from a lack of high-volume CleanCap orders, while Biologics Safety Testing revenue grew 7.2% to $16.3 million.
- The company projects full-year 2025 revenue to be approximately $185.0 million.
- Organizational restructuring and operating cost reduction initiatives are on track, with expectations for double-digit sequential revenue growth in the TriLink segment for Q4.
Nov 6, 2025, 9:03 PM
Maravai LifeSciences Reports Q3 2025 Financial Results
MRVI
Earnings
Guidance Update
Demand Weakening
- Maravai LifeSciences reported Q3 2025 revenue of $41.6 million, a 39.7% year-over-year decrease, resulting in a net loss of $(45.1) million and Adjusted EBITDA of $(10.8) million.
- The revenue decline was primarily due to a 52.9% decrease in Nucleic Acid Production revenue to $25.4 million, driven by a lack of high-volume CleanCap orders, while Biologics Safety Testing revenue grew 7.2% to $16.3 million.
- The company provided full-year 2025 revenue guidance of approximately $185.0 million.
- Management noted that organizational restructuring and cost reduction initiatives are on track, with expectations for double-digit sequential revenue growth from TriLink in Q4.
Nov 6, 2025, 9:01 PM
Maravai LifeSciences Reports Second Quarter 2025 Financial Results and Strategic Updates
MRVI
Earnings
Management Change
Guidance Update
- Maravai LifeSciences reported Q2 2025 revenue of $47.4 million, a 31.7% decrease year-over-year, alongside a net loss of $(69.8) million (including a $30.4 million goodwill impairment) and Adjusted EBITDA of $(10.4) million.
- The company announced an organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized savings, with expected restructuring charges of $8.0 million to $9.0 million in the second half of 2025.
- Bernd Brust was appointed as the new Chief Executive Officer and Raj Asarpota as Chief Financial Officer, and the company expects to achieve Net Loss Reduction, Positive Adjusted EBITDA, and Positive Free Cash Flow by the second half of 2026.
- Maravai has withdrawn and suspended its revenue guidance for full year 2025 as the new leadership team conducts a comprehensive business review.
Aug 11, 2025, 8:08 PM
Quarterly earnings call transcripts for MARAVAI LIFESCIENCES HOLDINGS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more